Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation |
| |
| Affiliation: | 1. Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150086, PR China;2. Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150086, PR China;1. Department of Pharmacology, Therapeutics and Toxicology, Faculty of Basic Medical Sciences, College of Medicine, University of Lagos, PMB 12003, Idi-araba, Lagos, Nigeria;2. Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Lagos, Lagos, Nigeria;1. Gillies McIndoe Research Institute, New Zealand;2. University of Auckland, New Zealand;3. Centre for the Study & Treatment of Vascular Birthmarks, Wellington Regional Plastic, Maxillofacial & Burns Unit, New Zealand;4. Department of Paediatrics, Hutt Hospital, Wellington, New Zealand;1. Academic Section of Urology, Division of Cancer Research, School of Medicine, University of Dundee, Scotland;2. Department of Radiation Oncology, Ninewells Hospital, National Health Service Tayside, Dundee, Scotland;3. Department of Cardiology, Division of Cardiovascular and Diabetes, School of Medicine, University of Dundee, Scotland;4. Tayside Clinical Trials Unit, School of Medicine, University of Dundee, Scotland;1. State Civil Servant Hospital (IAMSPE), São Paulo, Brazil;2. Oncology/Hematology Discipline, ABC Medical School, Santo André, São Paulo, Brazil;3. Paulista University, São Paulo, Brazil;4. Institute of Chemical and Pharmaceutical Sciences, UNIFESP, Diadema, São Paulo, Brazil;1. Oncology Department, Kaiser Permanente Colorado, Lone Tree, CO;2. Institute for Health Research, Kaiser Permanente Colorado, Denver, CO;3. Division of Research, Kaiser Permanente Northern California, Oakland, CA;4. Pharmacy Department, Kaiser Permanente Colorado, Aurora, CO;5. The Center for Health Research, Kaiser Permanente Northwest, Portland, OR;6. Edwin L. Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA;7. Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA;8. Division of Hematology and Oncology, Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, CA |
| |
| Abstract: | The aim of this study was to observe the clinical efficacy of fluvastatin combined with benazepril in the treatment of patients with atrial fibrillation (AF). A total of 92 patients with AF were randomly assigned to the case group (n = 46), in which the patients were treated with fluvastatin (80 mg) plus benazepril (10 mg), or to the control group (n = 46), in which the patients were treated with fluvastatin (80 mg). The conversion rate of sinus rhythm was higher in the case group than in the control group (P < 0.05). The case group had more treatment-effective patients than the control group, with fewer treatment-ineffective patients (P < 0.05). The LVEDd, LVESd, LAD, and LVEF indexes in the case group were lower than in the control group after 6 months of treatment (all P < 0.05). Levels of hs-CRP were also lower in patients in the case group than in patients in the control group after 1 month of treatment (P < 0.05). After 12 months, renin and Ang II concentrations were lower in patients in the case group than in the control group (both P < 0.05). Significant differences in IL-6 and TNF-α expression were found between the two groups after 1 month, 6 months, and 12 months of treatment (all P < 0.05). Compared to patients in the control group, the levels of total cholesterol (TC), triglycerides, and LDL-C in the case group were lower after 6 and 12 months of treatment (all P < 0.05), while the HDL level was higher (P < 0.05). Treatment with fluvastatin combined with benazepril further increased the conversion rate of sinus rhythm and significantly improved the quality of life and prognosis of AF patients. |
| |
| Keywords: | Fluvastatin Benazepril Atrial fibrillation Sinus rhythm conversion rate hs-CRP Renin Ang II IL-6 TNF-α |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
